ArticleFrontiers in pediatrics2025
Case Report: A rare pediatric case of hepatitis B virus infection with acute disseminated encephalomyelitis/Guillain-Barré syndrome spectrum diseases.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 12-year-old girl with convulsions was incidentally found to be infected with hepatitis B virus(HBV), with HBVdeoxyribonucleic acid (DNA) and HBsAg positivity in the cerebrospinal fluid. The patient experienced frequent convulsions and consciousness disorders, and positive anti-GQ1b/anti-GD1b antibodies were detected in the cerebrospinal fluid. Acute disseminated encephalomyelitis(ADEM)/Guillain-Barré syndrome (GBS) spectrum disorders were observed on brain and spinal cord magnetic resonance imaging, indicating a high likelihood of HBV-related ADEM+/GBS spectrum disorders. After treatment with intravenous hormone, immunoglobulin, antiviral therapy using entecavir, and antiepileptic medication, the neurological damage completely resolved, the hepatitis B viral load decreased significantly, and liver function returned to normal. ADEM+/GBS spectrum diseases are immune-mediated disorders of the central nervous system that occur after viral infection. However, the potential relationship between hepatitis B virus infection and ADEM+/GBS spectrum diseases remains an area of ongoing investigation. In this case, the combination of hormones and intravenous immunoglobulin did not affect the anti-HBV effect of entecavir, and the patient fully recovered from the neurological damage within three months of disease onset. This case highlights hepatitis B-related neurological diseases and encourages further sharing of clinical experiences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.